Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.32 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.32 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400638 | 0.88 | HCRTR2 (0.31) | — | |
| SCHEMBL4684407 | 0.84 | MC4R (0.37) | MAPTMAPK1KMT2ANPSR1 | |
| SCHEMBL4680812 | 0.84 | CACNA1G (0.34) | BRD4SMARCA2SMARCA4PBRM1MEN1 | |
| SCHEMBL6405908 | 0.80 | MAPT (0.36) | MEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL6400642 | 0.72 | IGF1R (0.34) | MEN1KMT2A | |
| SCHEMBL4742825 | 0.72 | CACNA1G (0.33) | MEN1MAPTKMT2A | |
| SCHEMBL4680817 | 0.70 | SMN1; SMN2 (0.36) | MAPT | |
| SCHEMBL4787561 | 0.70 | ALDH1A1 (0.34) | MEN1KMT2A | |
| SCHEMBL4684410 | 0.69 | ALDH1A1 (0.37) | MEN1MAPTMAPK1KMT2ANPSR1 | |
| SCHEMBL4680646 | 0.68 | ENPP2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1437349-B9 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2008-09-10 | — | — | EP | disclosed |
| EP-1437349-B1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2007-08-15 | — | — | EP | disclosed |
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2005-01-20 | — | — | US | disclosed |
| EP-1437349-A1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | XDH, SCO2, HAX1 | BRD4 880/4885SMARCA2 2604/4885SMARCA4 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.